10% Off
Jardian10 mg
Beximco Pharmaceuticals Ltd.
৳225.00
Add to cart
Empa10 mg
Tablet
By
Best PriceTk /
1
Alternatives
Price
Medicine overview
Indications of Empa 10 mg
Empa 10 mg is indicated in:
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Theropeutic Class
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Pharmacology
Empa 10 mg is a sodium glucose co-transporter-2 (SGLT-2) inhibitor.
Absorption
SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney.
Distribution
Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.
Excretion
The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion.
Dosage & Administration of Empa 10 mg
The recommended dose of Empa 10 mg is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empa 10 mg, the dose may be increased to 25 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of Empa 10 mg is recommended.
Dosage of Empa 10 mg
The recommended dose of Empa 10 mg is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empa 10 mg, the dose may be increased to 25 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of Empa 10 mg is recommended.
Interaction of Empa 10 mg
Diuretics: Co-administration of Empa 10 mg with diuretics resulted in increased urine volume. Insulin or Insulin Secretagogues: Co-administration of Empa 10 mg with insulin or insulin secretagogues increases the risk for hypoglycemia. Positive Urine Glucose Test: Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative methods to monitor glycemic control. Interference with 1,5-anhydroglucitol (1,5-AG) Assay: Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.
Contraindications
Empa 10 mg is contraindicated in patients with history of serious hypersensitivity reaction to Empa 10 mg or any of its ingredients, severe renal impairment, end-stage renal disease, or dialysis.
Side Effects of Empa 10 mg
The most common adverse reactions associated with Empa 10 mg are urinary tract infections and female genital mycotic infections. Others common side effects includes dehydration, hypotension, weakness, dizziness and increased thirstiness.
Pregnancy & Lactation
There are no adequate and well-controlled studies of Empa 10 mg in pregnant women. Empa 10 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Empa 10 mg is excreted in human milk. It is not recommended when breastfeeding.
Precautions & Warnings
Assessment of renal function is recommended prior to initiation of Empa 10 mg and periodically thereafter. Empa 10 mg should not initiated in patients with an eGFR less than 45 ml/min/1.73 m2. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 ml/min/1.73 m2.
Overdose Effects of Empa 10 mg
In the event of an overdose with Empa 10 mg the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, perform clinical monitoring, and institute supportive treatment) should be employed. Removal of Empa 10 mg by hemodialysis has not been studied.
Storage Conditions
Keep in a cool & dry place (below 30° C), protected from light & moisture. Keep out of the reach of children.
Drug Classes
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Mode Of Action
Empa 10 mg is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.
Pregnancy
There are no adequate and well-controlled studies of Empa 10 mg in pregnant women. Empa 10 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Empa 10 mg is excreted in human milk. It is not recommended when breastfeeding.
Frequently Asked Questions
What is Empa 10 mg used for?
Empagliflozin is indicated in: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
What is the dosage of Empa 10 mg?
The recommended dose of Empagliflozin is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empagliflozin, the dose may be increased to 25 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of Empagliflozin is recommended.
What are the side effects of Empa 10 mg?
The most common adverse reactions associated with Empagliflozin are urinary tract infections and female genital mycotic infections. Others common side effects includes dehydration, hypotension, weakness, dizziness and increased thirstiness.
Who should not take Empa 10 mg?
Empagliflozin is contraindicated in patients with history of serious hypersensitivity reaction to Empagliflozin or any of its ingredients, severe renal impairment, end-stage renal disease, or dialysis.
What precautions should be taken with Empa 10 mg?
Assessment of renal function is recommended prior to initiation of Empagliflozin and periodically thereafter. Empagliflozin should not initiated in patients with an eGFR less than 45 ml/min/1.73 m2. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 ml/min/1.73 m2.
Is Empa 10 mg safe during pregnancy and breastfeeding?
There are no adequate and well-controlled studies of Empagliflozin in pregnant women. Empagliflozin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Empagliflozin is excreted in human milk. It is not recommended when breastfeeding.
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.